A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Conditions: Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia

Sex: All

Ages: 3 Years – 21 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 100

Sponsor: Chongqing Precision Biotech Co., Ltd

Location: Beijing Children's Hospital.Capital Medical University Beijing Beijing Municipality

Summary

This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Eligibility Criteria

Inclusion Criteria: 1. The patient himself or his guardian agrees to participate in this clinical trial and signs the Informed Consent Form (ICF), indicating that he understands the purpose and procedures of this clinical trial and is willing to participate in the research; 2. Diagnosed with B-ALL，and meet one of the following conditions: 1. Refractory B-ALL: early-stage refractory patients who failed to achieve complete remission after 2 courses of standard induction chemotherapy; 2. Relapsed B-ALL: patients with early relapse (\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05334823). StuddyBuddy aggregates publicly available trial information.